Immunic, Inc. (NASDAQ:IMUX) Director Buys $100,395.00 in Stock

Immunic, Inc. (NASDAQ:IMUX) Director Richard Alan Rudick bought 87,300 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was purchased at an average cost of $1.15 per share, with a total value of $100,395.00. Following the completion of the transaction, the director now directly owns 87,300 shares in the company, valued at $100,395. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Immunic Price Performance

Shares of IMUX opened at $1.06 on Friday. Immunic, Inc. has a 52-week low of $0.97 and a 52-week high of $2.11. The stock’s 50-day simple moving average is $1.44 and its 200 day simple moving average is $1.35.

Institutional Investors Weigh In On Immunic

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in shares of Immunic in the first quarter valued at approximately $25,000. Jane Street Group LLC lifted its stake in Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after purchasing an additional 42,383 shares in the last quarter. State Street Corp grew its position in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after purchasing an additional 11,642 shares in the last quarter. Finally, Ikarian Capital LLC increased its holdings in shares of Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after purchasing an additional 1,162,378 shares during the period. 51.82% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on the company. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Leerink Partners restated an “outperform” rating and set a $5.00 price target on shares of Immunic in a report on Monday, September 9th. EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a research report on Monday, September 16th. Leerink Partnrs raised shares of Immunic to a “strong-buy” rating in a research report on Monday, September 9th. Finally, B. Riley started coverage on Immunic in a research report on Tuesday, August 27th. They set a “buy” rating and a $6.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Immunic has an average rating of “Buy” and an average price target of $12.25.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.